In human melanoma, colon cancer, breast cancer, and other cancer types, IL-32 can be induced by tumor necrosis factor (TNFα and IFNγ to inhibit cancer development, and its high expression may be related to the therapeutic effect of PD1 (Bhat et al., 2017; Paz et al., 2019). Here, TNF is linked to breast cancer.